Luminar Technologies Stock (NASDAQ: LAZR)

Luminar Technologies (NASDAQ:LAZR) Stock

Luminar Technologies

Luminar Technologies Inc is an automotive technology company ushering in a new era of vehicle safety and autonomy. It operates its business through the following segments: Autonomy Solutions and Advanced Technologies and Services. The majority of its revenue is generated from the Autonomy Solutions segment, which engages in the design, manufacturing, and sale of LiDAR sensors, catering mainly to the OEMs in the automobile, commercial vehicle, robo-taxi, and adjacent industries. The Advanced Technologies and Services segment provides semiconductors and related components, as well as design, test, and consulting services to the Autonomy Solutions segment and various third-party customers. Geographically, the company derives its key revenue from North America.

Luminar Technologies, Inc. - Class A Common Stock

Luminar Technologies Inc

Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) is set to give its latest quarterly earnings report on Thursday, 2025-06-26. Here's what investors need to know before the announcement.
Analysts estimate that Orion Energy Sys will report an earnings per share (EPS) of $-0.03. 
Investors in Orion Energy Sys are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Performance in Previous Earnings</h3>
The company's EPS missed by $0.04 in the last quarter, leading to a 1.85% drop in the share price on the following day.
Here's a look at Orion Energy Sys's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.01</td>
<td>-0.07</td>
<td>-0.08</td>
<td>-0.07</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.05</td>
<td>-0.11</td>
<td>-0.12</td>
<td>0.05</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-3.0%</td>
<td>2.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1750885274_0.png" alt="eps graph" />
<h3>Market Performance of Orion Energy Sys's Stock</h3>
Shares of Orion Energy Sys were trading at $0.5919 as of June 24. Over the last 52-week period, shares are down 51.84%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/OESX/earnings">To track all earnings releases for Orion Energy Sys visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

OESX

Insights into Orion Energy Sys's Upcoming Earnings

HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) is preparing to release its quarterly earnings on Thursday, 2025-06-26. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect HIVE Digital Technologies to report an earnings per share (EPS) of $-0.11.
Anticipation surrounds HIVE Digital Technologies's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
The company's EPS beat by $0.12 in the last quarter, leading to a 1.1% increase in the share price on the following day.
Here's a look at HIVE Digital Technologies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.11</td>
<td>-0.09</td>
<td>-0.01</td>
<td>-0.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.01</td>
<td>-0.06</td>
<td>0.03</td>
<td>-0.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-8.0%</td>
<td>2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1750885257_0.png" alt="eps graph" />
<h3>Performance of HIVE Digital Technologies Shares</h3>
Shares of HIVE Digital Technologies were trading at $1.85 as of June 24. Over the last 52-week period, shares are down 43.85%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/HIVE/earnings">To track all earnings releases for HIVE Digital Technologies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HIVE

HIVE Digital Technologies's Earnings: A Preview

Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-06-26. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Concentrix will report an earnings per share (EPS) of $2.75.
Anticipation surrounds Concentrix's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.20, leading to a 42.38% increase in the share price the following trading session.
Here's a look at Concentrix's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.59</td>
<td>3.01</td>
<td>2.93</td>
<td>2.62</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.79</td>
<td>3.26</td>
<td>2.87</td>
<td>2.69</td>
</tr>
<tr>
<td>Price Change %</td>
<td>42.0%</td>
<td>3.0%</td>
<td>-19.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1750885251_0.png" alt="eps graph" />
<h3>Performance of Concentrix Shares</h3>
Shares of Concentrix were trading at $54.08 as of June 24. Over the last 52-week period, shares are down 13.7%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analyst Insights on Concentrix</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Concentrix.
Analysts have provided Concentrix with 4 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $58.0, suggesting a potential 7.25% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Verra Mobility, CSG Systems Intl and TaskUs, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Verra Mobility, with an average 1-year price target of $26.88, suggesting a potential 50.3% downside.</li>
<li>Analysts currently favor an Neutral trajectory for CSG Systems Intl, with an average 1-year price target of $58.0, suggesting a potential 7.25% upside.</li>
<li>Analysts currently favor an Neutral trajectory for TaskUs, with an average 1-year price target of $16.5, suggesting a potential 69.49% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Verra Mobility, CSG Systems Intl and TaskUs, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concentrix</td>
<td>Neutral</td>
<td>-1.27%</td>
<td>$855.90M</td>
<td>1.66%</td>
</tr>
<tr>
<td>Verra Mobility</td>
<td>Outperform</td>
<td>6.45%</td>
<td>$210.44M</td>
<td>11.45%</td>
</tr>
<tr>
<td>CSG Systems Intl</td>
<td>Neutral</td>
<td>1.46%</td>
<td>$144.96M</td>
<td>5.70%</td>
</tr>
<tr>
<td>TaskUs</td>
<td>Neutral</td>
<td>22.12%</td>
<td>$106.61M</td>
<td>4.16%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Concentrix ranks in the middle among its peers for revenue growth, with a slight decline. It is at the bottom for gross profit, indicating lower profitability. However, Concentrix is at the top for return on equity, showing strong performance in generating profits relative to shareholders' equity.
<h3>All You Need to Know About Concentrix</h3>
Concentrix Corp is a technology enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five industry verticals. The Company's verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Frances and Others. Maximum revenue is from Technology and consumer electronics industry and geographically from Philippines.
<h3>Key Indicators: Concentrix's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Concentrix faced challenges, resulting in a decline of approximately -1.27% in revenue growth as of 28 February, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Concentrix's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 2.82%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Concentrix's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.66%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Concentrix's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.56%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Concentrix's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.22.
<a href="https://www.benzinga.com/quote/CNXC/earnings">To track all earnings releases for Concentrix visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CNXC

Preview: Concentrix's Earnings

Enerpac Tool Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAC#NYSE">EPAC</a>) is preparing to release its quarterly earnings on Thursday, 2025-06-26. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Enerpac Tool Group to report an earnings per share (EPS) of $0.47.
Investors in Enerpac Tool Group are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.01, leading to a 8.39% increase in the share price on the subsequent day.
Here's a look at Enerpac Tool Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.40</td>
<td>0.41</td>
<td>0.53</td>
<td>0.47</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.39</td>
<td>0.40</td>
<td>0.50</td>
<td>0.47</td>
</tr>
<tr>
<td>Price Change %</td>
<td>8.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1750885242_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Enerpac Tool Group were trading at $43.36 as of June 24. Over the last 52-week period, shares are up 13.51%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/EPAC/earnings">To track all earnings releases for Enerpac Tool Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EPAC

Earnings Preview: Enerpac Tool Group

Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) is preparing to release its quarterly earnings on Thursday, 2025-06-26. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Walgreens Boots Alliance to report an earnings per share (EPS) of $0.34.
Investors in Walgreens Boots Alliance are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Performance in Previous Earnings</h3>
The company's EPS beat by $0.11 in the last quarter, leading to a 1.79% increase in the share price on the following day.
Here's a look at Walgreens Boots Alliance's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.52</td>
<td>0.37</td>
<td>0.36</td>
<td>0.71</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.63</td>
<td>0.51</td>
<td>0.39</td>
<td>0.63</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>28.000000000000004%</td>
<td>6.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1750885233_0.png" alt="eps graph" />
<h3>Walgreens Boots Alliance Share Price Analysis</h3>
Shares of Walgreens Boots Alliance were trading at $11.35 as of June 24. Over the last 52-week period, shares are down 7.22%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/WBA/earnings">To track all earnings releases for Walgreens Boots Alliance visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Walgreens Boots Alliance's Earnings Forecast

In the current market session, Bank of New York Mellon Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) stock price is at $90.00, after a 1.32% drop. However, over the past month, the company's stock increased by 1.35%, and in the past year, by 51.16%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1750885228_0.png" alt="Past Year Chart" />

<h3>Comparing Bank of New York Mellon P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Bank of New York Mellon has a lower P/E than the aggregate P/E of 34.88 of the Capital Markets industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750885228_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

News

Intraday Update

Markets

P/E Ratio Insights for Bank of New York Mellon

Acuity Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-06-26. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Acuity Brands will report an earnings per share (EPS) of $4.49.
Anticipation surrounds Acuity Brands's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
The company's EPS beat by $0.03 in the last quarter, leading to a 9.2% drop in the share price on the following day.
Here's a look at Acuity Brands's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>3.70</td>
<td>3.89</td>
<td>4.28</td>
<td>4.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>3.73</td>
<td>3.97</td>
<td>4.30</td>
<td>4.15</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-9.0%</td>
<td>3.0%</td>
<td>0.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1750885225_0.png" alt="eps graph" />
<h3>Acuity Brands Share Price Analysis</h3>
Shares of Acuity Brands were trading at $284.44 as of June 24. Over the last 52-week period, shares are up 18.55%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analysts' Perspectives on Acuity Brands</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Acuity Brands.
The consensus rating for Acuity Brands is Neutral, derived from 6 analyst ratings. An average one-year price target of $295.0 implies a potential 3.71% upside.
<h3>Comparing Ratings with Competitors</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Nextracker, Regal Rexnord and Generac Hldgs, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Nextracker, with an average 1-year price target of $62.75, suggesting a potential 77.94% downside.</li>
<li>Analysts currently favor an Buy trajectory for Regal Rexnord, with an average 1-year price target of $148.57, suggesting a potential 47.77% downside.</li>
<li>Analysts currently favor an Buy trajectory for Generac Hldgs, with an average 1-year price target of $156.62, suggesting a potential 44.94% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for Nextracker, Regal Rexnord and Generac Hldgs, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acuity</td>
<td>Neutral</td>
<td>11.08%</td>
<td>$468M</td>
<td>3.11%</td>
</tr>
<tr>
<td>Nextracker</td>
<td>Outperform</td>
<td>25.50%</td>
<td>$305.69M</td>
<td>10.33%</td>
</tr>
<tr>
<td>Regal Rexnord</td>
<td>Buy</td>
<td>-8.37%</td>
<td>$527.60M</td>
<td>0.90%</td>
</tr>
<tr>
<td>Generac Hldgs</td>
<td>Buy</td>
<td>5.94%</td>
<td>$371.99M</td>
<td>1.77%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Acuity Brands ranks in the middle for revenue growth among its peers. It has the lowest gross profit and return on equity compared to others.
<h3>Delving into Acuity Brands's Background</h3>
Acuity is a leading industrial technology company that offers lighting, lighting controls, and intelligent building solutions. Acuity, Inc. designs, manufactures, and brings to market products and services relating to these and other offerings. Acuity, Inc. has two reportable segments: Acuity Brands Lighting and Acuity Intelligent Spaces. ABL sells commercial, architectural, and specialty lighting, including components and control systems. AIS offers building management and audio/visual solutions to help make buildings intelligent.
<h3>Acuity Brands: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Acuity Brands's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.08% as of 28 February, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Acuity Brands's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.7%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Acuity Brands's ROE excels beyond industry benchmarks, reaching 3.11%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Acuity Brands's ROA stands out, surpassing industry averages. With an impressive ROA of 1.84%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.47.
<a href="https://www.benzinga.com/quote/AYI/earnings">To track all earnings releases for Acuity Brands visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Acuity Brands's Quarterly Earnings

RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) has outperformed the market over the past 10 years by 6.73% on an annualized basis producing an average annual return of 18.16%. Currently, RBC Bearings has a market capitalization of $11.97 billion. 
Buying $1000 In RBC: If an investor had bought $1000 of RBC stock 10 years ago, it would be worth $5,331.61 today based on a price of $380.57 for RBC at the time of writing.
<h3>RBC Bearings's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750885217_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

General

Vor Bio Announces $175M Private Placement Of 700M Warrants At A Price Of $0.25 Per Warrant

<a href="https://www.sec.gov/Archives/edgar/data/1137883/000110465925062607/tm2518806d1_s3.htm">https://www.sec.gov/Archives/edgar/data/1137883/000110465925062607/tm2518806d1_s3.htm</a>

Offerings

BCLI

Brainstorm Cell Therapeutics Files Prospectus For Offer & Sale Of Up To 2.8M Shares Of Common Stock By Selling Stockholder

-Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis
-RemeGen receives initial payment of $125 million consisting of an upfront payment of $45 million plus $80 million of warrants, potential regulatory and commercial milestones exceeding $4 billion, as well as tiered royalties
-Seasoned biopharma leader, Jean-Paul Kress, MD, appointed as Chief Executive Officer and Chairman of the Board, bringing proven track record in clinical development, commercialization, and strategic growth
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) and RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331) today announced entry into an exclusive license agreement granting Vor Bio global rights (excluding China, Hong Kong, Macau and Taiwan) to develop and commercialize telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Under the terms of the agreement, Vor Bio will pay RemeGen an initial payment of $125 million consisting of an upfront payment of $45 million as well as $80 million of warrants to purchase common stock with an exercise price of $0.0001 per share. The agreement also provides for potential regulatory and commercial milestones exceeding $4 billion, in addition to tiered royalties.
Telitacicept is a novel, investigational fusion protein that targets key immune pathways involved in autoimmune disease. By selectively inhibiting BlyS (also known as BAFF) and APRIL - cytokines critical to B cell survival - telitacicept reduces autoreactive B cells and autoantibody production. RemeGen is conducting a global Phase 3 clinical trial which is now enrolling in the United States, Europe, and South America, with initial results expected in the first half of 2027.

Biotech

Contracts

Management

Vor Bio Licenses Ex-Greater China Rights To Telitacicept From RemeGen In $125M Deal With Milestones Over $4B; Appoints Jean-Paul Kress As CEO And Chairman

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) has outperformed the market over the past 10 years by 3.76% on an annualized basis producing an average annual return of 15.18%. Currently, PTC has a market capitalization of $20.29 billion. 
Buying $1000 In PTC: If an investor had bought $1000 of PTC stock 10 years ago, it would be worth $4,111.19 today based on a price of $168.60 for PTC at the time of writing.
<h3>PTC's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750884324_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Evertz Technologies (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ET#TSX">ET</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.16 by 6.25 percent. This is a 5.56 percent decrease over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $127.805 million which beat the analyst consensus estimate of $126.550 million by 0.99 percent. This is a 4.10 percent increase over sales of $122.770 million the same period last year.

Earnings Beats

TSX:ET

Evertz Technologies Q4 EPS $0.17 Beats $0.16 Estimate, Sales $127.805M Beat $126.550M Estimate

Amesite Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMST#NASDAQ">AMST</a>), a leading developer of AI-powered enterprise solutions, today announced that its flagship app, NurseMagic&#x2122;, now supports charting in 16 languages. This major enhancement is designed to address a key barrier to success for nearly 1 million nurses in the U.S. who speak English as a second language (ESL) — accounting for 19.2% of the nursing workforce — and to chart more efficiently and with greater confidence.
This multilingual capability positions Amesite to meet immediate market needs. Markets now able to leverage the platform include:
<ul>
<li>ESL nurses in the United States: Nearly 20% of U.S. nurses have English as a Second Language (ESL)</li>
<li>International healthcare systems treating U.S. patients: There are over 6.5 Million nurses in the top 10 medical tourist destinations for U.S. patients alone.</li>
<li>Private clinics in multilingual regions: The private sector provides nearly 40% of all healthcare in PAHO, AFRO, and WPRO regions, 57% in SEARO, and 62% in EMRO.</li>
</ul>

AMST

Amesite Expands NurseMagic To Support Charting In 16 Languages, Enhancing Efficiency For ESL Nurses And Global Healthcare Providers

Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) reported quarterly losses of $(24.64) per share. This is a 71.44 percent increase over losses of $(86.27) per share from the same period last year.

Color Star Tech H1 EPS $(24.64) Up From $(86.27) YoY

Micron Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) reported financial results for the third quarter of fiscal 2025 after the market close on Wednesday. Here&#8217;s what you need to know <a href="https://www.benzinga.com/pressreleases/25/06/g46103361/micron-technology-inc-reports-results-for-the-third-quarter-of-fiscal-2025">from the report</a>.
Q3 Earnings: Micron reported third-quarter revenue of $9.3 billion, beating the&nbsp;<a href="https://www.benzinga.com/quote/MU/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $8.87 billion. The company reported third-quarter adjusted earnings of $1.91 per share, beating analyst estimates of $1.60 per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Total revenue was up roughly 16% on a year-over-year basis. Operating cash flow came in at $4.61 billion versus $3.94 billion in the prior quarter and $2.48 billion in the comparable quarter last year. The company generated $1.95 billion in adjusted free cash in the third quarter.
&#8220;Micron delivered record revenue in fiscal third quarter, driven by all-time-high DRAM revenue, including nearly 50% sequential growth in HBM revenue. Data center revenue more than doubled year-over-year and reached a quarterly record, and consumer-oriented end markets had strong sequential growth,&#8221; said Sanjay Mehrotra, president and CEO of Micron.
Micron ended the period with $12.22 billion in cash,&nbsp;marketable investments and restricted cash. Micron&#8217;s board declared a quarterly dividend of $0.115 per share, payable on July 22 to shareholders of record as of July 7.
Outlook: Micron expects fourth-quarter revenue of $10.7 billion, plus or minus $300 million, versus estimates of $9.88 billion. The company anticipates fourth-quarter adjusted earnings of $2.50 per share, plus or minus 15 cents, versus estimates of $2.01 per share.
&#8220;We are on track to deliver record revenue with solid profitability and free cash flow in fiscal 2025, while we make disciplined investments to build on our technology leadership and manufacturing excellence to satisfy growing AI-driven memory demand,&#8221; Mehrotra said.
Micron&#8217;s management team will further discuss details of the quarter on a call with analysts and investors at 4:30 p.m. ET.
MU Price Action: <a href="https://www.benzinga.com/quote/MU" target="_blank" rel="noreferrer noopener">Micron shares</a> were up 3.74% in after-hours Wednesday, trading at $132 at the time of publication, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46099614/aerovironment-posts-better-than-expected-earnings-joins-quantumscape-bumble-blackberry-and-other-big-stocks-moving-higher-on-wednesday">AeroVironment Posts Better-Than-Expected Earnings, Joins QuantumScape, Bumble, BlackBerry And Other Big Stocks Moving Higher On Wednesday</a></li>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46098656/nvidia-amazon-tesla-among-tech-stocks-hedge-funds-are-piling-into-heres-how-etfs-like-ivv-spy-voo-are-riding-the-wave">Nvidia, Amazon, Tesla Among Tech Stocks Hedge Funds Are Piling Into — Here&#8217;s How ETFs Like IVV, SPY, VOO Are Riding The Wave</a></li>
</ul>
Photo: Shutterstock.

Guidance

After-Hours Center

Movers

Micron Q3 Earnings: Revenue, EPS Beat Estimates As Data Center Revenue More Than Doubles, Strong Guidance On Rising AI-Driven Demand

<a href="https://x.com/dorajfacundo/status/1937954599601623118" title="https://x.com/dorajfacundo/status/1937954599601623118">https://x.com/dorajfacundo/status/1937954599601623118</a>

Legal

Capital Forum Reporter Jarod Facundo Posts On X 'EXCLUSIVE - DOJ Antitrust leadership is considering changing the direction of its ongoing investigation into UnitedHealth Group to focus on the company's PBM, inspired by President Trump's drug pricing executive order and comments criticizing health care "middlemen."'

<a href="https://www.sec.gov/Archives/edgar/data/1365767/000121390025057818/ea0246875-424b5_allotltd.htm">https://www.sec.gov/Archives/edgar/data/1365767/000121390025057818/ea0246875-424b5_allotltd.htm</a>

ALLT

Allot Files For Offering Of Up To 5M Ordinary Shares

Atlantic Lottery to leverage IGT's next-generation, cloud-based IntelligenEVO technology to enhance system performance and player experience
LONDON, June 25, 2025 /PRNewswire/ -- International Game Technology PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) announced today that its subsidiary, IGT Canada Solutions ULC (hereinafter "IGT"), signed an eight-year agreement with Atlantic Lottery to supply its IntelligenEVO&#x2122; video lottery central system technology across Atlantic Canada. The agreement includes the option for multiple extensions and positions the Atlantic Lottery to become the first World Lottery Association ("WLA")-affiliated lottery operator to deploy IGT's next-generation central management system in a game-to-system ("G2S") distributed market.

International Game Technology's IGT Canada Signs 8-Yr Agreement With Atlantic Lottery To Supply IntelligenEVO Video Lottery Central System Technology Across Atlantic Canada

<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001624512/000162828025033028/boxl-20250619.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/0001624512/000162828025033028/boxl-20250619.htm</a>

BOXL

Boxlight Greg Wiggins Resigns As CFO; To Remain As CFO Until July 18, 2025

Press Releases

Luminar Obtains $200 Million Capital Commitment to Bolster Balance Sheet & Liquidity

Luminar Improves Capital Structure with Repurchase of $50 Million in 2026 Convertible Senior Notes

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Luminar Technologies, Inc. - LAZR

Penny Stocks

LAZR Investors Have Opportunity to Join Luminar Technologies, Inc. Fraud Investigation with the Schall Law Firm

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of Luminar Technologies, Inc. (NASDAQ: LAZR) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Comments

Luminar Technologies

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL